Exelixis
EXEL
#1635
Rank
ยฃ7.88 B
Marketcap
ยฃ28.15
Share price
-1.44%
Change (1 day)
49.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of December 2024 : ยฃ1.73 Billion

According to Exelixis's latest financial reports the company has ยฃ1.73 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2024-12-31$ยฃ1.78 B0.64%
2023-12-31$ยฃ1.77 B-13.61%
2022-12-31$ยฃ2.05 B25.6%
2021-12-31$ยฃ1.63 B18.79%
2020-12-31$ยฃ1.37 B7.22%
2019-12-31$ยฃ1.28 B26.76%
2018-12-31$ยฃ1.01 B381.04%
2017-12-31$ยฃ0.21 B191.28%
2016-12-31$ยฃ72.38 M-176.18%
2015-12-31$-ยฃ95.02 Million28.83%
2014-12-31$-ยฃ73.76 Million-283.67%
2013-12-31$ยฃ40.15 M-78.11%
2012-12-31$ยฃ0.18 B214.53%
2011-12-31$ยฃ58.31 M-139.42%
2010-12-31$-ยฃ0.15 Billion46.19%
2009-12-31$-ยฃ0.11 Billion163.57%
2008-12-31$-ยฃ38.39 Million-189.18%
2007-12-31$ยฃ43.04 M-6.95%
2006-12-31$ยฃ46.25 M39.23%
2005-12-31$ยฃ33.22 M25.88%
2004-12-31$ยฃ26.39 M-70.76%
2003-12-31$ยฃ90.27 M-17.72%
2002-12-31$ยฃ0.10 B-32.94%
2001-12-31$ยฃ0.16 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
ยฃ12.70 B 631.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ62.68 B 3,510.16%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ35.87 B 1,966.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ12.67 B 630.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ4.54 B 161.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ55.31 B 3,085.54%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ68.47 B 3,843.37%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.76 Million-100.39%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ22.31 M-98.71%๐Ÿ‡บ๐Ÿ‡ธ USA